Biotechnology company Moderna, Inc. (NASDAQ: MRNA) has reported a net loss for the fourth quarter of 2024, compared to a profit last year.
- Total revenue for the fourth quarter was $1.0 billion, compared to $2.8 billion in the same period of FY23
- Net product sales for the quarter were $938 million, reflecting a 66% year-over-year decrease
- The company reported a net loss of $1.1 billion for the December quarter, compared to net income of $217 million in Q4 2023
- On a per-share basis, net loss was $2.91 in the fourth quarter, compared to earnings per share of $0.55 in the prior-year quarter
- Cost of sales for Q4 came in at $739 million, which included third-party royalties of $45 million, inventory write-downs of $193 million, and wind-down costs of $259 million
- Research and development expenses decreased by 20% to $1.1 billion during the three months
- Cash, cash equivalents, and investments as of December 31, 2024, were $9.5 billion, compared to $9.2 billion as of September 30, 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
StubHub Holdings set to enter public markets. Here’s what to expect
After a modest start to the year, the IPO market is witnessing an increase in activity led by technology and healthcare companies. StubHub Holdings, a leading online ticket marketplace for
Can Beyond Meat (BYND) overcome its persistent challenges?
Shares of Beyond Meat, Inc. (NASDAQ: BYND) stayed red on Tuesday. The stock has dropped 19% over the past three months. The plant-based meat company continues to struggle in terms
CarMax (KMX) likely to report strong earnings growth for Q4 2025
After reporting robust earnings growth for the third quarter, CarMax, Inc. (NYSE: KMX) is preparing to publish Q4 results next week. Over the years, the company has fostered customer loyalty
